BNTC: Benitec Price-to-Revenue Coefficient

Symbol and logo of brand Benitec Biopharma Inc (BNTC)

Benitec Biopharma Inc. (BNTC) is developing an innovative environment based on gene silencing technologies, monetizing its unique intellectual property. The company's average P/S reflects market valuation dynamics, with the metric fixed at 8841.90. Meanwhile, the production of therapeutic molecules is fully delegated to certified partners, and the operating model relies on the outsourcing of clinical trials to minimize capital expenditures.

BNTC Benitec Corp Price-to-Revenue Ratio (07/04/2022 - 09/27/2024)

Analytical breakdowns for Benitec (BNTC)

- current price and projected stock value:
Price Chart benitec.com|BNTC - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Benitec|BNTC - Total Company Value
- company book value details:
Net Asset Value per Share Benitec Biopharma|BNTC - Company Book Value|Market Capitalization to Net Assets benitec.com|BNTC - Company Total Assets
- issuer credit burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Benitec Biopharma Inc.|BNTC - Long-Term Debt to Capital|Short-Term Debt to Capital Benitec Corp|BNTC - Company Debts|Debt to Net Assets Ratio Benitec|BNTC - Company Long-Term Debt|Company Current Liabilities Benitec Biopharma|Quick Ratio benitec.com
- earnings and multiples data:
BNTC - Net Income|Expected Net Income Benitec Biopharma Inc.|BNTC - P/E Multiple|Market Cap to Projected Earnings Benitec Biopharma Inc|BNTC - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Benitec|BNTC - Operating profit EBITDA|Net earnings per share for the last 12 months Benitec Biopharma|BNTC - Net earnings per share for the last 12 months|Year-over-year net earnings per share change for the last twelve months benitec.com|BNTC - Earnings growth in current year|Net earnings per share growth forecast for next year Benitec Biopharma Inc.
- total revenue and sales volume data:
BNTC - Company Revenue|Company Revenue Forecast benitec.com|BNTC - Market Cap to Revenue|Price to Expected Revenue Ratio Benitec
Fundamental company analysis:benitec.com, BNTC
Finished products of Benitec

For Benitec Biopharma Inc. (BNTC), the efficiency of gene therapy logistics and the resilience of biomedical hubs directly determine the market value of every unit of generated revenue. By analyzing the price-to-sales multiple, an investor compares market capitalization with actual revenue to determine the premium paid for future growth; a decrease in this ratio amid stable sales signals undervalued assets and potential for capital appreciation.

Competitors of Benitec Biopharma Inc.

Price-to-Revenue Ratio TEM (Tempus AI)|P/S Multiple QGEN (Qiagen)|Price-to-Revenue Coefficient Ionis Pharmaceuticals, Inc. (IONS)|RGEN - Price-to-Revenue Ratio|Price to Sales Avidity Corp|CRISPR Therapeutics AG (CRSP) - Price-to-Revenue Ratio|Price-to-Sales Ratio WGS (genedx.com)|RARE (Ultragenyx) - P/S Multiple|BEAM: Market Capitalization-to-Revenue Ratio|P/S Multiple SRPT|P/S Multiple Twist Bioscience Corp (TWST)|Price-to-Revenue Ratio 10x Genomics, Inc. TXG|Market Capitalization-to-Revenue Ratio NTLA|STOK - Price-to-Revenue Ratio|BioLife Solutions Inc (BLFS) - Market Cap to Revenue|WVE: P/S Multiple|Maze Therapeutics Corp (MAZE) - P/S Multiple|Market Cap to Revenue SION|PRME: Market Capitalization-to-Revenue Ratio|P/S Multiple TSHA|Price-to-Revenue Coefficient uniQure NV|Price-to-Revenue Ratio MeiraGTx PLC MGTX|RGNX: Market Cap to Revenue Ratio|Solid Biosciences Inc. - P/S Multiple|ocugen.com (OCGN) - Market Cap to Revenue|PACB (PacBio) - Market Cap to Revenue|DSGN - Price-to-Revenue Coefficient|RCKT (Rocket Pharmaceuticals Inc) - P/S Multiple|Price-to-Revenue Ratio FDMT|Price-to-Revenue Ratio Lexeo Therapeutics (LXEO)|korrobio.com - Market Cap to Revenue Ratio|Editas Medicine - Market Cap to Revenue|Market Cap to Sales Volume SLN (Silence Therapeutics PLC)|ProQR Therapeutics NV - P/S Multiple|Codexis, Inc. (CDXS) - Market Cap to Revenue|SGMO: P/S Multiple|Market Cap to Revenue Ratio NAUT|Price-to-Revenue Ratio Metagenomi|Market Cap to Revenue Ratio DTIL (precisionbiosciences.com)|P/S Multiple GBIO|P/S Multiple Boundless Bio Inc (BOLD)|P/S Multiple XCUR (Exicure)|Imunon Inc - Price-to-Revenue Ratio|RXi Pharmaceuticals - P/S Multiple|Price to Sales Mustang Bio, Inc.|transcodetherapeutics.com (RNAZ) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio BNGO|APDN (Applied DNA Sciences) - P/S Multiple|bluebirdbio.com (BLUE) - Price-to-Revenue Coefficient|Market Cap to Revenue IPA (ImmunoPrecise Antibodies)|Market Cap to Sales Volume OMGA|P/S Multiple OMIC (Singular Genomics Systems Inc)|Regulus (RGLS) - Price to Sales|Syros Pharmaceuticals - P/S Multiple|telesisbio.com (TBIO) - Market Cap to Revenue|TCON (TRACON Pharmaceuticals, Inc.) - Market Cap to Revenue|Unity Biotechnology Inc. - Market Capitalization-to-Revenue Ratio